Economic Evaluation of Dapagliflozin as Add-On to Metformin in T2DM in the Israeli Health Care Setting

被引：1
|
作者：
Moshel, Shai
Vexberg, Michal Hirsch
Shavit, Oren
Toledano, Yoel
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-1297-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Metformin safety in T2DM patients with psoriasis
    Reactions Weekly, 2019, 1743 (1) : 10 - 10
  • [42] Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes
    Mueller-Wieland, Dirk
    Kellerer, Monika
    Cypryk, Katarzyna
    Skripova, Dasa
    Rohwedder, Katja
    Johnsson, Eva
    Garcia-Sanchez, Ricardo
    Kurlyandskaya, Raisa
    Sjostrom, C. David
    Jacob, Stephan
    Seufert, Jochen
    Dronamraju, Nalina
    Csomos, Katalin
    DIABETES OBESITY & METABOLISM, 2018, 20 (11): : 2598 - 2607
  • [43] ASSESSING ADHERENCE TO SGLT2 INHIBITOR ADD-ON TO METFORMIN THERAPY IN CHINESE T2DM PATIENTS: A REAL-WORLD RETROSPECTIVE COHORT STUDY
    Bao, H.
    Jian, Y.
    Peng, X.
    Xuan, J.
    VALUE IN HEALTH, 2024, 27 (06) : S308 - S308
  • [44] Empagliflozin as Add-on to Linagliptin and Metformin in Patients with Type 2 Diabetes (T2DM): Subgroup Analysis by Baseline Demographics in a 24-Week Randomized Trial
    Seufert, Jochen
    Naderali, Ebrahim
    Maldonaldo, Mario
    Del Parigi, Angelo
    Toorawa, Robert
    Lee, Christopher
    DIABETES, 2016, 65 : A292 - A292
  • [45] COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS ADD-ON TO METFORMIN FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Tzanetakos, C.
    Tentolouris, N.
    Kourlaba, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2015, 18 (07) : A606 - A607
  • [46] The Cost-Effectiveness of Canagliflozin (CANA) vs. Sitagliptin as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the US
    Martin, Silas
    Neslusan, Cheryl
    Vo, Lien
    Teschemaker, Anna
    Johansen, Pierre
    Willis, Michael
    DIABETES, 2014, 63 : A310 - A310
  • [47] DAPAGLIFLOZIN: COST EFFECTIVENESS AS AN ADD-ON THERAPY TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES IN ECUADOR
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Sanchez, Solis C.
    Acosta, W.
    Solorzano, J.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2016, 19 (03) : A202 - A202
  • [48] Randomised, double-blind trial of dual add-on saxagliptin plus dapagliflozin vs saxagliptin or dapagliflozin add-on alone in poorly controlled type 2 diabetes on metformin
    Hansen, L.
    Zee, P.
    Li, Y.
    Cook, W.
    Hirshberg, B.
    Iqbal, N.
    Rosenstock, J.
    DIABETOLOGIA, 2014, 57 : S8 - S8
  • [49] Dapagliflozin associated with higher risk of ketoacidosis in T2DM patients
    Reactions Weekly, 2022, 1900 (1) : 6 - 6
  • [50] Dapagliflozin Is Safe and Well Tolerated in Older Patients with T2DM
    Mansfield, Traci
    Fioretto, Paola
    Ptaszynska, Agata
    Yavin, Yshai
    Apanovitch, Anne Marie
    Johnsson, Eva
    Parikh, Shamik J.
    List, James F.
    DIABETES, 2014, 63 : A71 - A71
12345